PTPRM

Across TCGA pan-cancer cohorts, PTPRM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPRM data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTPRM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTPRM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PTPRM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.293	0.512	<.001	70	view →
LUAD	OS	Tertile	II,III,IV	0.280	1.000	<.001	68	view →
CCRCC	OS	Quartile	All	0.951	0.732	.022	27	view →
LSCC	OS	Tertile	All	0.925	1.000	.042	4	view →
GBM	OS	Tertile	All	0.706	0.400	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPRM–PDAC (DFS)

Open the PDAC breakdown →